{"database": "lobbying", "table": "lobbying_activities", "rows": [[1195829, "b706d751-d004-4bb2-99df-fcc027c2719f", "Q4", "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION", 31348, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION", 2011, "fourth_quarter", "PHA", "H.R. 1409:  All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274:  All provisions of the Medication Therapy Management Benefits Act of 2011;  H.R. 905 /S. 733:All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; H.R. 979All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act\n\nH.R. 605 / S. 312All provisions of the Patients Freedom to Choose Act \n\nS. 27            All provisions of the Preserve Access to Affordable Generics Act \n\nS. 31All provisions of the Prescription Drug and Health Improvement Act of 2011\n\nS. 44All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011\n\nH.R. 999 / S. 560All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011\n\nH.R. 1839                              All provisions of the Community Pharmacy Fairness Act of 2011;\n\nH.R. 1946                              All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011;\n\nH.R. 1971 / S. 1058             All provisions of the Pharmacy Competition and Consumer Choice Act of 2011\n\nProvisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap\n\nRegulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio)\n\nRegulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors\n\nImplementation of changes to the definition of Average Manufacturer Price in Medicaid\n\nIssues related to the management of Medicaid prescription drug benefits\n\nLegislation to promote generic drugs\n\nFDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs\n\n340b program\n\nH.R. 2672  the Preserving Access to Orphan Drugs Act\n\nH.R. 2182  the Generating Antibiotic Incentives Now Act\n\nH.R. 3026  the Safeguarding Americas Pharmaceuticals Act\n\nH.R. 2746  the Cancer Drug Coverage Parity Act", "Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE", null, 446695, 0, 0, "2012-01-19T13:39:43-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1195829"], "units": {}, "query_ms": 0.3000518772751093, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}